Allogene Therapeutics has received a grant of $15m from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of its allogeneic CAR T product, ALLO-316.
ALLO-316 is an AlloCAR T investigational product that targets CD70 being developed to treat advanced or metastatic renal cell carcinoma (RCC).
Go deeper with GlobalData
The grant will fund the ongoing Phase I TRAVERSE clinical trial, which is evaluating the safety, tolerability, and preliminary efficacy of ALLO-316 in patients with advanced or metastatic RCC.
Initial data from the trial indicated promising response rates and early anti-tumour activity.
The study’s participants, who have advanced RCC that has progressed despite standard therapy, have shown deepening responses over time, highlighting a significant unmet medical need.
ALLO-316 utilises Dagger technology to selectively eliminate CD70 positive, alloreactive host immune cells.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis approach aims to delay or prevent the patient’s immune system from prematurely rejecting the AlloCAR T cells.
The technology has demonstrated the potential to optimise CAR T cell expansion and persistence, which has been evident in both preclinical experiments and patient responses in the clinical trial.
The CIRM grant is intended to support the completion of the Phase I trial segment and the expansion of clinical sites, which will increase access for diverse patient populations.
It will also fund translational and clinical analyses to determine a recommended Phase II regimen.
CIRM therapeutics development vice-president Dr Abla Creasey said: “This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need.”
In March 2022, ALLO-316 obtained the US Food and Drug Administration’s fast track designation recognising its potential to meet the needs of patients with RCC who have not responded to standard therapies.
Earlier this year, Allogene said it was discontinuing two of its Phase II trials investigating its ‘off-the-shelf’ cell therapy in advanced large B-cell lymphoma (LBCL) patients, to focus on using it as a first-line consolidation therapy.
